- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07876557
A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
A Phase II Study of JS212 Monotherapy or Combination Therapy With JS207 or JS001 in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
This is an phase II study to prelininarily evaluate the efficacy and safety of JS212 mono therapy or combination therapy in patients with recurrent or metastatic TNBC.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study consists of 2 parts. Both parts consist of safety run-in period and cohort expansion period. Safety run-in period will enroll those who have received only 1 line of prior systemic standard treatment. Cohort expansion period will enroll those are treated naive or recived treatment in adjuvant phase.
Part 1 will receive JS212 monotherapy or combination therapy with JS207, based on the PD-L1 expression. Part 2 will receive JS212 in combination with JS001.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Chaoqiang Yang, PM
- Phone Number: 18252095266
- Email: chaoqiang_yang@junshipharma.com
Study Locations
-
-
-
Beijing, China
- Recruiting
- Peking University People's Hospital
-
Contact:
- Shu Wang, PhD.
- Phone Number: 13801080201
- Email: dr.wangshu@263.net
-
Principal Investigator:
- Shu Wang, Ph.D.
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100144
- Not yet recruiting
- Peking University Shougang Hospital
-
Contact:
- Xueli Mo, Master
- Phone Number: 13699180225
- Email: xuelimo@hotmail.com
-
Principal Investigator:
- Xueli Mo, Master
-
Beijing, Beijing Municipality, China, 100071
- Not yet recruiting
- The Fifth Medical Center of Chinese PLA General Hospital
-
Contact:
- Shaohua Zhang, Doctor
- Phone Number: 13311591557
- Email: zhangsh19760428@163.com
-
Principal Investigator:
- Shaohua Zhang, Doctor
-
-
Fujian
-
Fuzhou, Fujian, China, 350000
- Not yet recruiting
- Fujian Cancer Hospital
-
Contact:
- Fan Wu, Ph.D.
- Phone Number: 13859082118
- Email: wufan_fj@163.com
-
Principal Investigator:
- Fan Wu, Ph.D.
-
-
Gansu
-
Lanzhou, Gansu, China, 730000
- Not yet recruiting
- The First Hospital of Lanzhou University
-
Contact:
- Xiaoling Ling, Ph.D.
- Phone Number: 18693165668
- Email: lingxiaolingedu@163.com
-
Principal Investigator:
- Xiaoling Ling, Ph.D.
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Not yet recruiting
- Sun Yat-sen University Cancer Center
-
Contact:
- Shusen Wang, Ph.D.
- Phone Number: 13926168469
- Email: wangshs2019@163.com
-
Principal Investigator:
- Shusen Wang, Ph.D.
-
Guangzhou, Guangdong, China, 510080
- Not yet recruiting
- Guangdong General Hospital
-
Contact:
- Kun Wang, Ph.D.
- Phone Number: 13922118086
- Email: bzwangkun@163.com
-
Principal Investigator:
- Kun Wang, Ph.D.
-
-
Guizhou
-
Guiyang, Guizhou, China, 550004
- Not yet recruiting
- The Affiliated Hospital of Guizhou Medical University
-
Contact:
- Shu Liu, Ph.D.
- Phone Number: 13908516963
- Email: drliushu@163.com
-
Principal Investigator:
- Shu Liu, Ph.D.
-
Guiyang, Guizhou, China, 550001
- Not yet recruiting
- The Affiliated Cancer Hospital of Guizhou Medical University City: Guiyang
-
Contact:
- Zhihong Wang, Bachelor
- Phone Number: 13595159308
- Email: Wzh1968626@sina.com
-
Principal Investigator:
- Zhihong Wang, Bachelor
-
-
Hebei
-
Baoding, Hebei, China, 071000
- Not yet recruiting
- Affiliated Hospital of Hebei University
-
Contact:
- Hua Yang, Ph.D.
- Phone Number: 18603120729
- Email: docyh@163.com
-
Principal Investigator:
- Hua Yang, Ph.D.
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150081
- Not yet recruiting
- Harbin Medical University Cancer Hospital
-
Contact:
- Wenhui Zhao, Ph.D.
- Phone Number: 18745177632
- Email: zhaowenhui1977@163.com
-
Principal Investigator:
- Wenhui Zhao, Ph.D.
-
-
Henan
-
Zhengzhou, Henan, China, 450001
- Not yet recruiting
- The First Affiliated Hospital of Zhengzhou University
-
Contact:
- Hong Zong, Ph.D.
- Phone Number: 13623586882
- Email: zonghong522@126.com
-
Principal Investigator:
- Hong Zong, Ph.D.
-
Zhengzhou, Henan, China, 450002
- Not yet recruiting
- Henan Cancer Hospital
-
Contact:
- Min Yan, Ph.D.
- Phone Number: 15713857388
- Email: ym200678@126.com
-
Principal Investigator:
- Min Yan, Ph.D.
-
-
Hubei
-
Wuhan, Hubei, China, 430079
- Not yet recruiting
- Hubei Cancer Hospital
-
Contact:
- Xinhong Wu, Ph.D.
- Phone Number: 18602726300
- Email: Xinhongwuhbch@163.com
-
Principal Investigator:
- Xinhong Wu, Ph.D.
-
-
Hunan
-
Changde, Hunan, China, 415003
- Not yet recruiting
- The First People's Hospital of Changde City
-
Contact:
- Hui Li, Ph.D.
- Phone Number: 15886648808
- Email: 373099626@qq.com
-
Principal Investigator:
- Hui Li, Ph.D.
-
Changsha, Hunan, China, 410013
- Not yet recruiting
- Hunan Cancer Hospital
-
Contact:
- Quchang Ouyang, Ph.D.
- Phone Number: 13973135318
- Email: oyqc1969@126.com
-
Principal Investigator:
- Quchang Ouyang, Ph.D.
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Not yet recruiting
- Jiangsu Province Hospital
-
Contact:
- Wei Li, Ph.D.
- Phone Number: 13851603656
- Email: real.lw@163.com
-
Principal Investigator:
- Wei Li, Ph.D.
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330009
- Not yet recruiting
- Nanchang People's Hospital
-
Contact:
- Wenyan Chen, Bachelor
- Phone Number: 18679168977
- Email: chenwenyannc2013@163.com
-
Principal Investigator:
- Wenyan Chen, Bachelor
-
-
Jilin
-
Changchun, Jilin, China, 130021
- Not yet recruiting
- The First Hospital of Jilin University
-
Contact:
- Lihua Kang, Ph.D.
- Phone Number: 13504334518
- Email: kanglihua961002@163.com
-
Principal Investigator:
- Lihua Kang, Ph.D.
-
Changchun, Jilin, China, 130012
- Not yet recruiting
- Jilin Provincial Cancer Hospital
-
Contact:
- Fei Chen, Master
- Phone Number: 18604430968
- Email: Email:flyrcf@163.com
-
Principal Investigator:
- Fei Chen, Master
-
-
Liaoning
-
Shenyang, Liaoning, China, 110022
- Not yet recruiting
- Shengjing Hospital of China Medical University
-
Contact:
- Xihe Zhao, Ph.D.
- Phone Number: 18940259508
- Email: zhaoxh@sj-hospital.org
-
Principal Investigator:
- Xihe Zhao, Ph.D.
-
Shenyang, Liaoning, China, 110042
- Not yet recruiting
- Cancer Hospital of Dalian University of Technology(Liaoning Cancer Hospital & Institute)
-
Contact:
- Tao Sun, Ph.D.
- Phone Number: 13940404526
- Email: lnzlrxnsy@163.com
-
Principal Investigator:
- Tao Sun, Ph.D.
-
Shenyang, Liaoning, China, 110167
- Not yet recruiting
- Introduction to the First Affiliated Hospital of China Medical University
-
Contact:
- Yuee Teng, Ph.D.
- Phone Number: 13591639797
- Email: tengyuee517@yahoo.com.cn
-
Principal Investigator:
- Yuee Teng, Ph.D.
-
-
Ningxia
-
Yinchuan, Ningxia, China, 750000
- Not yet recruiting
- General Hospital of Ningxia Medical University
-
Contact:
- Ye Lv, Bachelor
- Phone Number: 18709515757
- Email: liuweilvye@yeah.net
-
Principal Investigator:
- Ye Lv, Bachelor
-
-
Shandong
-
Jinan, Shandong, China, 250117
- Not yet recruiting
- Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital)
-
Contact:
- Qi Dang, Master
- Phone Number: 15318816098
- Email: dangqi123456@126.com
-
Contact:
- Huihui Li, Ph.D.
- Phone Number: 15553103209
- Email: 15553103209@163.com
-
Principal Investigator:
- Huihui Li, Ph.D.
-
Jining, Shandong, China, 272000
- Not yet recruiting
- Affiliated Hospital of Jining Medical University
-
Contact:
- Changping Shan, Master
- Phone Number: 18678766865
- Email: scp9933@163.com
-
Principal Investigator:
- Changping Shan, Master
-
Qingdao, Shandong, China, 266000
- Not yet recruiting
- The Affiliated Hospital of Qingdao University
-
Contact:
- Haibo Wang, Ph.D.
- Phone Number: 18661805787
- Email: hbwangqy@126.com
-
Principal Investigator:
- Haibo Wang, Ph.D.
-
Weifang, Shandong, China, 261000
- Not yet recruiting
- Weifang People's Hospital
-
Contact:
- Wenhui Wang, Ph.D.
- Phone Number: 18605368857
- Email: wwh8857@163.com
-
Principal Investigator:
- Wenhui Wang, Ph.D.
-
-
Shanxi
-
Taiyuan, Shanxi, China, 030013
- Not yet recruiting
- Shanxi Cancer Hospital
-
Contact:
- Guohui Han, Ph.D.
- Phone Number: 13754858188
- Email: 13754858188@163.com
-
Principal Investigator:
- Guohui Han, Ph.D.
-
-
Sichuan
-
Chengdu, Sichuan, China, 610072
- Not yet recruiting
- Sichuan Provincial People's Hospital
-
Contact:
- Jing Luo, Ph.D.
- Phone Number: 18981838521
- Email: jingluopi@163.com
-
Principal Investigator:
- Jing Luo, Ph.D.
-
Mianyang, Sichuan, China
- Not yet recruiting
- Mianyang Central Hospital
-
Contact:
- Zhen zhang, Master
- Phone Number: 13778159530
- Email: jiangzhangtong@sina.com
-
Principal Investigator:
- Zhen Zhang, Master
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female age 18-70 years old;
- Voluntary participation in clinical study;
- Histologically confirmed unresectable, locally advanced or metastatic triple-negative breast cancer(absence of HER2, ER, and PR expression);
- No prior systemic antitumor therapy for locally advanced or Metastatic TNBC(cohort expansion period); only one line of prior systemetic treatment for locally advanced or metastatic TNBC;
- Adequate organ function;
- ECOG performance status of 0 or 1;
- Life expectancy 12 weeks;
- Measurable disease, as defined by RECIST v1.1;
Exclusion Criteria:
- Untreated or active central nervous system (CNS) metastases;
- Uncontrolled pleural effusion, pericardial effusion or ascites;
- Tumor encasement of important vessels or significant necrosis and cavitation that may cause a risk of hemorrhage;
- History of significant bleeding tendency or severe coagulation disorder;
- Uncontrolled hypertension;
- Active autoimmune diseases requiring systemic treatmen within 2 years prior to the first dose;
- History of interstitial lung disease or previous Noninfectious pneumonitis treated with corticosteroids, or evidence of active Pneumonia in radiology on screening period;
- History of immunodeficiency. Presence of active tuberculosis, hepatitis B, or hepatitis C;
- Severe cardiovascular disease;
- Serious infection (CTCAE 6.0 Grade>2) within 28 days prior to the first dose of study drug;
- Previous treatment of any anti-VRGF drugs targeting VEGF (part 1) or ADC drugs targeting EGFR and/or HER3;
- History of another malignancy within 5 years before the first dose of study drug;
- Not suitable to receive study treatment for other conditions as per investigator;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Cohort A
JS212 in combination with JS207,CPS≥10 |
JS212 and JS207 will be administered intravenously on D1, Q3W |
|
Experimental: Cohort B
JS212 monotherapy, CPS<10 |
JS212 will be administered intravenously on D1,Q3W |
|
Experimental: Cohort C
JS212 in combination with JS207, CPS<10 |
JS212 and JS207 will be administered intravenously on D1, Q3W |
|
Experimental: Cohort D
JS212 in combination with JS001 |
JS212 and JS001 will be administered intravenously on D1, Q3W |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective response rate(ORR)
Time Frame: 24 months
|
Objective response rate(ORR) evaluated based on RECIST v1.1 |
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Duration of response (DoR)
Time Frame: 24 months
|
Duration of response (DoR) evaluated based on RECIST v1.1 |
24 months
|
|
Disease control rate (DOR)
Time Frame: 24 months
|
Disease control rate (DOR)evaluated based on RECIST v1.1 |
24 months
|
|
Progression free survival (PFS)
Time Frame: 24 months
|
Progression free survival (PFS) evaluated based on RECIST v1.1 |
24 months
|
|
Overall Survival (OS)
Time Frame: 36 months
|
Overall Survival (OS)evaluated based on RECIST v1.1 |
36 months
|
|
Adverse Events
Time Frame: 24 months
|
Incidence and severity of Adverse Events(AEs)according to NCI-CTCAE v6.0 |
24 months
|
|
Immunogenicity
Time Frame: 24 months
|
The incidence of Nab(if applicable) of JS212 and JS207 |
24 months
|
|
Plasma concentrations
Time Frame: 2 years
|
Plasma concentrations of JS207 and 9MW2821 |
2 years
|
|
PD-L1 expression
Time Frame: 2 years
|
The correlation between PD-L1 expression in tumor tissue and therapeutic efficacy |
2 years
|
|
EGFR/HER expression
Time Frame: 2 years
|
The correlation between EGFR/HER3 expression in tumor tissue and therapeutic efficacy |
2 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- JS212-009-II-BC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.